This article is more than 5 years old. Information may no longer be current.

SciFluor's SF0166 eye drops show positive phase 1/2 results in wet AMD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

A phase 1/2 trial of SF0166 eye drops for wet age-related macular degeneration has shown positive top-line results, according to a press release from SciFluor Life Sciences.

The safety and tolerability, as well as preliminary efficacy, of SF0166 were evaluated in the 28-day double-masked study of 42 patients.

Subjects were randomized to self-administer an eye drop containing either a 2.5% or 5% solution of SF0166 twice a day, the release said. No serious drug-related events were observed during the 28-day treatment or 28-day follow-up; five subjects showed mild or moderate adverse ocular events, with one considered possibly drug-related.

Nine patients showed clinically significant biological activity including decreases in central retinal thickness and/or subretinal fluid, according to the release.

“Combined with our previously reported data in diabetic macular edema patients, we now have an impressive safety profile for SF0166 in over 80 patients coupled with distinct evidence of biological activity for both indications. This implies that the drug is not only well-tolerated but that it is reaching the back of the eye and is active,” Omar Amirana, MD, SciFluor’s CEO, said in the release.